Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel and Capecitabine in Head and Neck Cancer
NCT00148122Phase 2Completed
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Nov 2002
- Primary completion
- Aug 2008
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of docetaxel, capecitabine in head and neck cancer (HNC), sponsored by University of Michigan Rogel Cancer Center. Started Nov 2002; status: completed.
02
Drugs
docetaxelcapecitabine
03
Conditions
head and neck cancer (HNC)
Beyond the preview
Go deeper on NCT00148122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00148122.